Literature DB >> 29377436

Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population.

M Faber1, N Willrich1, M Schemmerer2, C Rauh2, R Kuhnert3, K Stark1, J J Wenzel2.   

Abstract

A steep rise in Hepatitis E diagnoses is currently being observed in Germany and other European countries. The objective of this study was (i) to assess whether this trend mirrors an increase in infection pressure or is caused by increased attention and testing and (ii) estimate individual and population-based Hepatitis E Virus (HEV) seroconversion and seroreversion rates for Germany. We measured anti-HEV IgG prevalence in 10 407 adults participating in two linked, population-representative serosurveys (total n = 12 971) conducted in 1998 and 2010. In this period, we found a moderate but statistically significant decline of overall anti-HEV IgG prevalence from 18.6% to 15.3%. At both time points, seroprevalence increased with age and peaked in persons born between 1935 and 1959 suggesting a past period of increased infection pressure. Paired samples of individuals participating in 1998 and 2010 (n = 2564) revealed respective seroconversion and seroreversion rates of 6.2% and 22.6% among seronegative and seropositive individuals during 12 years, or 5.2 and 2.9 per 1000 inhabitants per year. This corresponds to a total of 417 242 [95%CI: 344 363-495 971] new seroconversions per year in the German population. While anti-HEV seroprevalence has decreased in the last decade, infection pressure and seroincidence remains high in Germany. Continuously rising numbers of Hepatitis E diagnoses in Europe are likely due to an increased awareness of clinicians and indicate that still there is a gap between incident and diagnosed cases. Studies on the true burden of the disease, specific risk factors and sources of autochthonous infections as well as targeted prevention measures are urgently needed.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  anti-HEV IgG; epidemiology; foodborne infections; hepatitis E; longitudinal study; viral hepatitis

Mesh:

Substances:

Year:  2018        PMID: 29377436     DOI: 10.1111/jvh.12868

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  18 in total

1.  Hepatitis E virus infection prevalence among men who have sex with men involved in a hepatitis A virus outbreak in Italy.

Authors:  Enea Spada; Angela Costantino; Patrizio Pezzotti; Roberto Bruni; Giulio Pisani; Elisabetta Madonna; Paola Chionne; Matteo Simeoni; Umbertina Villano; Cinzia Marcantonio; Stefania Taffon; Giuseppe Marano; Simonetta Pupella; Giancarlo M Liumbruno; Anna R Ciccaglione
Journal:  Blood Transfus       Date:  2019-11       Impact factor: 3.443

2.  High prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders in eastern Poland.

Authors:  Anna Parfieniuk-Kowerda; Jerzy Jaroszewicz; Tadeusz W Łapiński; Mariusz Łucejko; Magdalena Maciaszek; Magdalena Świderska; Anna Grzeszczuk; Beata Naumnik; Mirosław Rowiński; Robert Flisiak
Journal:  Arch Med Sci       Date:  2018-12-05       Impact factor: 3.318

3.  Epidemiology and genotype 3 subtype dynamics of hepatitis E virus in Belgium, 2010 to 2017.

Authors:  Vanessa Suin; Sofieke E Klamer; Veronik Hutse; Magali Wautier; Marjorie Jacques; Mona Abady; Sophie Lamoral; Vera Verburgh; Isabelle Thomas; Bernard Brochier; Lorenzo Subissi; Steven Van Gucht
Journal:  Euro Surveill       Date:  2019-03

4.  Seroprevalence of hepatitis E virus in dromedary camels, Bedouins, Muslim Arabs and Jews in Israel, 2009-2017.

Authors:  R Bassal; M Wax; R Shirazi; T Shohat; D Cohen; D David; S Abu-Mouch; Y Abu-Ghanem; E Mendelson; Z Ben-Ari; O Mor
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

5.  Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment.

Authors:  Bernhard Schlevogt; Volker Kinast; Julia Reusch; Andrea Kerkhoff; Dimas Praditya; Daniel Todt; Hartmut H Schmidt; Eike Steinmann; Patrick Behrendt
Journal:  Pathogens       Date:  2019-08-22

6.  Clinical presentations of Hepatitis E: A clinical review with representative case histories.

Authors:  Abhishek Chauhan; Gwilym Webb; James Ferguson
Journal:  Clin Res Hepatol Gastroenterol       Date:  2019-02-23       Impact factor: 2.947

7.  Hepatitis E Infection in a Longitudinal Cohort of Hepatitis C Virus and HCV/HIV Coinfected Persons.

Authors:  Kenneth E Sherman; Shyam Kottilil; Susan D Rouster; Enass A Abdel-Hameed; Ceejay L Boyce; Heidi L Meeds; Norah Terrault; M Tarek Shata
Journal:  AIDS Res Hum Retroviruses       Date:  2021-05-10       Impact factor: 1.723

8.  Case-control study on risk factors for acute hepatitis E in Germany, 2012 to 2014.

Authors:  Mirko Faber; Mona Askar; Klaus Stark
Journal:  Euro Surveill       Date:  2018-05

9.  Continuous decline of hepatitis E virus seroprevalence in southern Germany despite increasing notifications, 2003-2015.

Authors:  Hannah Mahrt; Mathias Schemmerer; Gundula Behrens; Michael Leitzmann; Wolfgang Jilg; Jürgen J Wenzel
Journal:  Emerg Microbes Infect       Date:  2018-07-25       Impact factor: 7.163

Review 10.  Meta-Analysis of Human IgG anti-HEV Seroprevalence in Industrialized Countries and a Review of Literature.

Authors:  Lisandru Capai; Alessandra Falchi; Rémi Charrel
Journal:  Viruses       Date:  2019-01-20       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.